Skip to main content

Table 1 Baseline clinical characteristics of the training and validation cohort

From: Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma

  Total (n = 151) Training (n = 103) Validation (n = 48) P values
Age(years), median (IQR) 58.0 (51.0, 67.0) 61.0 (50.3, 68.0) 56.0 (51.0, 64.0) 0.307
Gender, no.(%)     0.355
 Male 119 (78.8) 79 (76.7) 40 (83.3)  
 Female 32 (21.2) 24 (23.3) 8(16.7)  
ALT, (U/L), median (IQR) 33.5 (20.8, 47.8) 29.70 (20.7, 45.3) 35.4 (20.9, 52.9) 0.220
AST, (U/L), median (IQR) 33.0 (24.4, 44.1) 32.4 (24.5, 43.4) 33.9 (24.0, 49.8) 0.407
GGT, (U/L), median (IQR) 50.8 (29.2, 108.8) 49.6 (30.2, 92.7) 52.1 (27.9, 144.5) 0.771
AFP, (µg/L), median(IQR) 15.3 (3.1, 417.5) 15.5 (3.1, 527.4) 11.6 (2.9, 301.6) 0.718
AFP group.no(%)     0.555
 ≤ 20 µg/L 79 (52.3) 54 (52.4) 25 (52.1)  
 20–400 µg/L 34 (22.5) 21 (20.4) 13 (27.1)  
 > 400 µg/L 38 (25.2) 28 (27.2) 10 (20.8)  
Hepatitis B, no.(%)     0.856
 Negative 36 (23.8) 25 (24.3) 11 (22.9)  
 Positive 115 (76.2) 78 (75.7) 37 (77.1)  
Hepatitis C, no.(%)     1.000
 Negative 145 (96.0) 99 (96.1) 46 (95.8)  
 Positive 6 (4.0) 4 (3.9) 2 (4.2)  
Cirrhosis, no.(%)     0.520
 Negative 43 (28.5) 31 (30.1) 12 (25.0)  
 Positive 108 (71.5) 72 (69.9) 36 (75.0)  
Tumor grade, no.(%)     0.398
 Low-grade tumor 100 (66.2) 71(68.9) 29(60.4)  
 High-grade tumor 51(33.8) 32 (31.0) 19(39.6)  
  1. AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyltransferase